Evaluation of verteporfin pharmakokinetics redefining the need of photosensitizers in ophthalmology

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 8, 2012, Pages 1023-1041

  Ziemssen, Focke ^a   Heimann, Heinrich ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Central serous chorioretinopathy; Choroidal haemangioma; Choroidal melanoma; Choroidal neovascularization; Low fluence; Polypoidal choroidal vasculopathy; Retinal angioma; Verteporfin

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; DEXAMETHASONE; INDIUM CHLORIDE METHYL PYROPHEOPHORBIDE; KERASTICK; LUTETIUM TEXAPHYRIN; PHOTOFRIN; PHOTOPOINT; PHOTOSENSITIZING AGENT; RANIBIZUMAB; UNCLASSIFIED DRUG; VERTEPORFIN;

ANGIOMA; BLOOD VESSEL OCCLUSION; BRACHYTHERAPY; CENTRAL SEROUS RETINOPATHY; CHOROID MELANOMA; CHOROIDAL HEMANGIOMA; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEMANGIOMA; HUMAN; LASER; MONOTHERAPY; MYOPIA; NONHUMAN; OPHTHALMOLOGY; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINA MACULA AGE RELATED DEGENERATION; RETINAL ANGIOMA; REVIEW; RISK ASSESSMENT; SUBRETINAL NEOVASCULARIZATION;

CENTRAL SEROUS CHORIORETINOPATHY; CHOROID NEOPLASMS; CHOROIDAL NEOVASCULARIZATION; DRUG EVALUATION; HEMANGIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OPHTHALMOLOGY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84864063603     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.701617     Document Type: Review

References (204)

1. Brown DM, Michels M, Kaiser PK, ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65.e5
2. Bakri SJ, Kaiser PK. verteporfin ocular photodynamic therapy. Expert Opin Pharmacother 2004;5(1):195-203
3. Bressler NM, Chang TS, Fine JT, Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs photodynamic therapy: A randomized clinical trial. Arch Ophthalmol 2009;127(1):13-21
4. Oner A, Karakucuk S, Mirza E, Erkilic K. Electrooculography after photodynamic therapy. Doc Ophthalmol 2005;111(2):83-86
5. Tzekov R, Lin T, Zhang KM, et al. Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci 2006;47(1):377-385
6. Ozdemir H, Karacorlu SA, Karacorlu M. Early optical coherence tomography changes after photodynamic therapy in patients with age-related macular degeneration. Am J Ophthalmol 2006;141(3):574-576
7. Matsubara A, Nakazawa T, Husain D, et al. Investigating the effect of ciliary body photodynamic therapy in a glaucoma mouse model. Invest Ophthalmol Vis Sci 2006;47(6):2498-2507
8. You IC, Im SK, Lee SH, Yoon KC. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization. Cornea 2011;30(1):30-33
9. Moshfeghi DM, Peyman GA, Moshfeghi AA, et al. Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: Time dependencies. Ophthalmic Surg Lasers 1998;29(8):663-668
10. Renno RZ, Delori FC, Holzer RA, et al. Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 2000;41(12):3963-3971
11. Criswell MH, Ciulla TA, Lowseth LA, et al. Anastomotic vessels remain viable after photodynamic therapy in primate models of choroidal neovascularization. Invest Ophthalmol Vis Sci 2005;46(6):2168-2174
12. Obana A, Gohto Y, Kaneda K, et al. PDT to monkey CNV with ATX-S10 (Na): Inappropriateness of early laser irradiation for selective occlusion. Invest Ophthalmol Vis Sci 2001;42(11):2639-2645
13. Ciulla TA, Criswell MH, Snyder WJ, SmallWIV. Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris. Br J Ophthalmol 2005;89(1):113-119
14. Berdugo M, Bejjani RA, Valamanesh F, et al. Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes. Invest Ophthalmol Vis Sci 2008;49(4):1633-1644
15. Bullous AJ, Alonso CM, Boyle RW. Photosensitiser-antibody conjugates for photodynamic therapy. Photochem Photobiol Sci 2011;10(5):721-750
16. Miller JW. Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis). Trans Am Ophthalmol Soc 2008;106:357-382
17. Allison RR, Downie GH, Cuenca R, et al. Photodiag Photodynam Ther. 2004;1:27-42
18. Detty MR, Gibson SL, Wagner SJ. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem 2004;47:3897-3915
19. Jesionek A, von Tappenier H. Zur Behandlung der Hautcarcinome mit mit fluorescierenden Stoffen. Muench Med Wochenschr 1903;47:2042
20. Richter AM, Waterfield E, Jain AK, et al. In vitro evaluation of phototoxic properties of four structurally related benzoporphyrin derivatives. Photochem Photobiol 1990;52:495-500
21. Karsten AE, Singh A, Braun MW. Experimental verification and validation of a computer model for light-tissue interaction. Lasers Med Sci 2012;27(1):79-86
22. Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 2008;53(9):R61-109
23. Brancaleon L, Moseley H. Laser and non-laser light sources for photodynamic therapy. Lasers Med Sci 2002;17(3):173-186
24. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195-214
25. Ansari-Shahrezaei S, Ergun E, Chong R, et al. Magnification-corrected photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2007;245(3):333-337
26. Ansari-Shahrezaei S, Binder S, Stur M. The effect of laser unit on photodynamic therapy spot size. Graefes Arch Clin Exp Ophthalmol 2011;249(1):11-14
27. Ayaru L, Wittmann J, Macrobert AJ, et al. Photodynamic therapy using verteporfin photosensitization in the pancreas and surrounding tissues in the Syrian golden hamster. Pancreatology 2007;7(1):20-27
28. Barnes LD, Giuliano EA, Ota J. Cellular localization of Visudyne as a function of time after local injection in an in vivo model of squamous cell carcinoma: An investigation into tumor cell death. Vet Ophthalmol 2010;13(3):158-165
29. Richter AM, Kelly B, Chow J, et al. Preliminary studies on a more effective phototoxic agent than hematoporphyrin. J Natl Cancer Inst 1987;79(6):1327-1332
30. Rousset N, Vonarx V, Eĺeouet S, et al. Cellular distribution and phototoxicity of benzoporphyrin derivative and Photofrin. Res Exp Med (Berl) 2000;199(6):341-357
31. Donohue E, Tovey A, Vogl AW, et al. Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin. J Biol Chem 2011;286(9):7290-7300
32. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res 2001;21(6B):4271
33. Chen B, Pogue BW, Hoopes PJ, Hasan T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int J Radiat Oncol Biol Phys 2005;61(4):1216-1226
34. Schnurrbusch UE, Welt K, Horn LC, et al. Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy. Br J Ophthalmol 2001;85(9):1086-1091
35. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120(6):835-844
36. Moshfeghi DM, Kaiser PK, Grossniklaus HE, et al. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 2003;135(3):343-350
37. Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology 2005;112(12):2061-2069
38. Fingar VH, Kik PK, Haydon PS, et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br J Cancer 1999;79(11-12):1702-1708
39. He C, Agharkar P, Chen B. Intravital microscopic analysis of vascular perfusion and macromolecule extravasation after photodynamic vascular targeting therapy. Pharm Res 2008;25(8):1873-1880
40. Debefve E, Mithieux F, Perentes JY, et al. Leukocyte-endothelial cell interaction is necessary for photodynamic therapy induced vascular permeabilization. Lasers Surg Med 2011;43(7):696-704
41. Maar N, Pemp B, Kircher K, et al. Ocular haemodynamic changes after single treatment with photodynamic therapy assessed with non-invasive techniques. Acta Ophthalmol 2009;87(6):631-637
42. Tsuchihashi T, Mori K, Peyman G, et al. Photodynamic effects on retinal oxygen saturation, blood flow, and electrophysiological function in patients with neovascular age-related macular degeneration. Retina 2009;29(10):1450-1456
43. Petermeier K, Tatar O, Inhoffen W, et al. Grisanti S. verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes. Br J Ophthalmol 2006;90(8):1034-1039
44. Matsubara A, Nakazawa T, Noda K, et al. Photodynamic therapy induces caspase-dependent apoptosis in rat CNV model. Invest Ophthalmol Vis Sci 2007;48(10):4741-4747
45. Houle J, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol 2002;42:547-557
46. Richter AM, Kelly B, Chow J, et al. Preliminary studies on a more effective phototoxic agent than hematoporphyrin. J Natl Cancer Inst 1987;79(6):1327-1332
47. Richter AM, Cerruti-Sola S, Sternberg ED, et al. Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice. J Photochem Photobiol B 1990;5(2):231-244
48. Richter AM, Waterfield E, Jain AK, et al. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumour tissue in a mouse tumour model. Photochem Photobiol 1993;57:1000-1006
49. Richter AM, Waterfield E, Jain AK, et al. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model. Br J Cancer 1991;63:87-93
50. Allison BA, Pritchard PH, Richter AM, et al. The plasma distribution of benzoporphyrin derivative and the effects of plasma lipoproteins on its biodistribution. Photochem Photobiol 1990;52:501-507
51. Schmidt-Erfurth U, Hasan T, Schomacker K, et al. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med 1995;17(2):178-188
52. Richter AM, Yip S, Meadows H, et al. Photosensitizing potencies of the structural analogues of benzoporphyrin derivative in different biological test systems. J Clin Laser Med Surg 1996;14(5):335-341
53. Khanum F, Jain V. Cellular accumulation and biological activity of hematoporphyrin derivative (L) in comparison with photofrin II. Indian J Exp Biol 1997;35(4):348-355
54. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999;117(9):1161-1173
55. Jamieson CH, McDonald WN, Levy JG. Preferential uptake of benzoporphyrin derivative by leukemic versus normal cells. Leuk Res 1990;14(3):209-219
56. Chowdhary RK, Shariff I, Dolphin D. Drug release characteristics of lipid based benzoporphyrin derivative. J Pharm Pharm Sci 2003;6(1):13-19
57. Polo L, Valduga G, Jori G, Reddi E. Low-density lipoprotein receptors in the uptake of tumour photosensitizers by human and rat transformed fibroblasts. Int J Biochem Cell Biol 2002;34(1):10-23
58. Haimovici R, Kramer M, Miller JW, et al. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res 1997;16(2):83-90
59. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials TAP report. Arch Ophthalmol 1999;117(10):1329-1345
60. Bressler NM; Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials -TAP report 2. Arch Ophthalmol 2001;119(2):198-207
61. verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial -VIP report no. 1. Ophthalmology 2001;108:841-852
62. Blinder KJ, Blumenkranz MS, Bressler NM, et al. verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial -VIP report no. 3. Ophthalmology 2003;110:667-673
63. Bandello F, Blinder K, Bressler NM, et al. verteporfin in Photodynamic Therapy: Report no. 5. Ophthalmology 2004;111:2144
64. Kaiser PK; VIO study group. verteporfin PDT for subfoveal occult CNV in AMD: Two-year results of a randomized trial. Curr Med Res Opin 2009;25(8):1853-1860
65. Harding SP, Tomlin K. Reeves BC, et al. verteporfin Photodynamic Therapy Cohort Study: Report 1: EFFECTIVENESS and Factors Influencing Outcomes. Ophthalmology 2009;116:e1-8
66. Boyer DS, Antoszyk AN, Awh CC, MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114(2):246-252
67. Gharbiya M, Giustolisi R, Allievi F, et al. Choroidal neovascularization in pathologic myopia: Intravitreal ranibizumab versus bevacizumab-a randomized controlled trial. Am J Ophthalmol 2010;149(3):458-464
68. Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114(10):1868-1875
69. Keane PA, Heussen FM, Ouyang Y, et al. Assessment of Differential Pharmacodynamic Effects using Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 2012;53(3):1152-1161
70. Irigoyen C, Ziahosseini K, Morphis G, et al. Endophthalmitis following intravitreal injections. Graefes Arch Clin Exp Ophthalmol 2011;250(4):499-505
71. Lim LS, Cheung CM, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned? Am J Ophthalmol 2011;152(3):329-331
72. Debefve E, Cheng C, Schaefer SC, et al. Photodynamic therapy induces selective extravasation of macromolecules: Insights using intravital microscopy. J Photochem Photobiol B 2010;98(1):69-76
73. Ishikawa K, Nishihara H, Ozawa S, et al. Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2011;249(2):273-280
74. Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: The VIA study. Br J Ophthalmol 2010;94(2):174-179
75. Rudnisky CJ, Liu C, Ng M, et al. Intravitreal bevacizumab alone versus combined verteporfin photodynamic therapy and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: Visual acuity after 1 year of follow-up. Retina 2010;30:548-554
76. Vallance JH, Johnson B, Majid MA, et al. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye (Lond) 2010;24(10):1561-1567
77. Jyothi S, Chowdhury HR, Chong V, Sivaprasad S. Anti-VEGF therapy for choroidal neovascularisation previously treated with photodynamic therapy. Eye 2010;24:1018-1023
78. Kaiser PK, Boyer DS, Cruess AF, et al. verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of the DENALI study. Retina 2012;119(5):1001-1010
79. Larsen M, Schmidt-Erfurth U, Lanzette P, et al. verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study. Retina 2012;119(5):992-1000
80. Ciardella AP, Donsoff IM, Huang SJ, et al. Polypoidal choroidal vasculopathy. Surv Ophthalmol 2004;49(1):25-37
81. Chan WM, Lai TY, Tano Y, et al. Photodynamic therapy in macular diseases of asian populations: When East meets West. Jpn J Ophthalmol 2006;50(2):161-169
82. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;148(1):70-78
83. Stangos AN, Gandhi JS, Nair-Sahni J, et al. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 2010;150(5):666-673
84. Otani A, Sasahara M, Yodoi Y, et al. Indocyanine green angiography: Guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007;144(1):7-14
85. Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: Natural history. Am J Ophthalmol 2002;133:639-648
86. Oishi A, Mandai M, Kimakura M, et al. Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy. Eye 2011;25(8):1020-1026
87. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92(1):70-73
88. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: An interim 6-month report. Br J Ophthalmol 2010;94(3):297-301
89. Chan WM, Lam DS, Lai TY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: One-year results of a prospective case series. Ophthalmology 2004;111(8):1576-1584
90. Eandi CM, Ober MD, Freund KB, et al. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. Retina 2007;27(7):825-831
91. Koh A, Lee WK, Chen LJ, et al. Everest study: EFFICACY and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in Patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; E-Pub
92. Tomita K, Tsujikawa A, Yamashiro K, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol 2012;153(1):68-80
93. Yamashiro K, Tsujikawa A, Nishida A, et al. Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy. Jpn J Ophthalmol 2008;52:457-462
94. Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2011;55(1):39-44
95. Tsuchiya D, Yamamoto T, Kawasaki R, Yamashita H. Two year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina 2009;29:960-965
96. Sagong M, Lim S, Chang W. Reduced-Fluence Photodynamic Therapy Combined With Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy. Am J Ophthalmol 2012;153(5):873-882
97. Machida S, Nishimura T, Tamada K, et al. Macular function evaluated by focal macular electroretinograms after reduced fluence photodynamic therapy in eyes with polypoidal choroidal vasculopathy. Doc Ophthalmol 2011;124(2):91-98
98. Chan MC, Lim TH, Pece A, Silva R. Yoshimura N. verteporfin PDT for non-standard indications-a review of current literature. Graefes Arch Clin Exp Ophthalmol 2010;248:613-626
99. Imasawa M, Sakurada Y, Iijima H. Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2011;55(3):241-247
100. Barbazetto I, Schmidt-Erfurth U. Photodynamic therapy of choroidal hemangioma: Two case reports. Graefes Arch Clin Exp Ophthalmol 2000;238(3):214-221
101. Gambrelle J, Graswill C, Mauget-Faysse M, et al. Treatment of circumscribed choroidal haemangiomas by photodynamic therapy: A review. J Fr Ophtalmol 2010;33(7):497-504
102. Blasi MA, Tiberti AC, Scupola A, et al. Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: Five-year outcomes. Ophthalmology 2010;117(8):1630-1637
103. Landau IM, Steen B, Seregard S. Photodynamic therapy for circumscribed choroidal haemangioma. Acta Ophthalmol Scand 2002;80(5):531-536
104. Madreperla SA. Choroidal hemangioma treated with photodynamic therapy using verteporfin. Arch Ophthalmol 2001;119:1606-1610
105. Gupta M, Singh AD, Rundle PA, Rennie IG. Efficacy of photodynamic therapy in circumscribed choroidal haemangioma. Eye (Lond) 2004;18(2):139-142
106. Soucek P, Cihelkova I. Evaluation of subretinal fluid absorption by optical coherence tomography in circumscribed choroidal hemangioma after photodynamic therapy with verteporfin. Neuro Endocrinol Lett 2004;25(1-2):109-114
107. Verbraak FD, Schlingemann RO, de Smet MD, Keunen JE. Single spot PDT in patients with circumscribed choroidal haemangioma and near normal visual acuity. Graefes Arch Clin Exp Ophthalmol 2006;244(9):1178-1182
108. Michels S, Michels R, Simader C. Schmidt-Erfurth U. verteporfin therapy for choroidal hemangioma: A long-term follow-up. Retina 2005;25(6):697-703
109. Jurklies B, Anastassiou G, Ortmans S, et al. Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma. Br J Ophthalmol 2003;87(1):84-89
110. Pilotto E, Urban F, Parrozzani R, Midena E. Standard versus bolus photodynamic therapy in circumscribed choroidal hemangioma: Functional outcomes. Eur J Ophthalmol 2011;21(4):452-458
111. Gambrelle J, Graswill C, Mauget-Faysse M, et al. Treatment of circumscribed choroidal haemangiomas by photodynamic therapy: A review. J Fr Ophtalmol 2010;33(7):497-504
112. Porrini G, Giovannini A, Amato G, et al. Photodynamic therapy of circumscribed choroidal hemangioma. Ophthalmology 2003;110(4):674-680
113. Elizalde J, Vasquez L, Iyo F, Abengoechea S. Photodynamic therapy in the management of circumscribed choroidal hemangioma. Can J Ophthalmol 2012;47(1):16-20
114. Tsipursky MS, Golchet PR, Jampol LM. Photodynamic therapy of choroidal hemangioma in sturge-weber syndrome, with a review of treatments for diffuse and circumscribed choroidal hemangiomas. Surv Ophthalmol 2011;56(1):68-85
115. Boixadera A, Garcia-Arumi J, Martinez-Castillo V, et al. Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma. Ophthalmology 2009;116(1):100-5.e1
116. Wachtlin J, Spyridaki M, Stroux A, et al. Therapy for peripapillary located and large choroidal haemangioma with PDT 'paint-brush technique'. Klin Monbl Augenheilkd 2009;226(11):933-938
117. Tsipursky MS, Golchet PR, Jampol LM. Photodynamic therapy of choroidal hemangioma in sturge-weber syndrome, with a review of treatments for diffuse and circumscribed choroidal hemangiomas. Surv Ophthalmol 2011;56(1):68-85
118. Heimann H, Bornfeld N, Vij O, et al. Vasoproliferative tumours of the retina. Br J Ophthalmol 2000;84(10):1162-1169
119. Shields CL, Shields JA, Barrett J, De Potter P. Vasoproliferative tumors of the ocular fundus. Classification and clinical manifestations in 103 patients. Arch Ophthalmol 1995;113(5):615-623
120. Rennie IG. Retinal vasoproliferative tumors. Eye 2010;24:468-471
121. Rodriguez-Coleman H, Spaide RF, Yannuzzi LA. Treatment of angiomatous lesions of the retina with photodynamic therapy. Retina 2002;22:228-232
122. Barbezetto IA, Smith RT. Vasoproliferative tumor of the retima treated with PDT. Retina 2003;23(4):565-567
123. Blasi MA, Scupola A, Tiberti AC, et al. Photodynamic therapy for vasoproliferative retinal tumors. Retina 2006;26(4):404-409
124. Osman S, Aylin Y, Arikan G, et al. Photodynamic treatment of a secondary vasoproliferative tumour associated with sector retinitis pigmentosa and Usher syndrome type I. Clin Experiment Ophthalmol 2007;35:191-193
125. Saldanha MJ, Edrich C. Treatment of vasoproliferative tumors with photodynamic therapy. Ophthalmic Surg Lasers Imaging 2008;39:143-145
126. Chan RP, Lai TY. Photodynamic therapy with verteporfin for vasoproliferative tumour of the retina. Acta Ophthalmol 2010;88(6):711-712
127. Wong WT, Chew EY. Ocular von Hippel-Lindau disease: Clinical update and emerging treatments. Curr Opin Ophthalmol 2008;19(3):213-217
128. Atebara NH. Retinal capillary hemangioma treated with verteporfin photodynamic therapy. Am J Ophthalmol 2002;134(5):788-790
129. Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology 2002;109(7):1256-1266
130. Mennel S, Barbazetto I, Meyer CH, et al. Ocular photodynamic therapy-standard applications and new indications. Part 2. Review of the literature and personal experience. Ophthalmologica 2007;221(5):282-291
131. Sachdeva R, Dadgostar H, Kaiser PK, et al. verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmol 2010;88(8):e334-40
132. Cheung J, Lee GK, Tham CC. A large retinal capillary hemangioma in the anterior retina treated with photodynamic therapy. Case Report Ophthalmol 2012;3(1):1-4
133. Wong YM, Jalil A, Mathews J, Stanga PE. Exudative retinal detachment following photodynamic therapy for retinal capillary hemangioma. Can J Ophthalmol 2010;45(3):299-300
134. Baba T, Kitahashi M, Kubota-Taniai M, et al. Subretinal hemorrhage after photodynamic therapy for juxtapapillary retinal capillary hemangioma. Case Report Ophthalmol 2011;2(1):134-139
135. Ach T, Thiemeyer D, Hoeh AE, et al. Intravitreal bevacizumab for retinal capillary haemangioma: Longterm results. Acta Ophthalmol 2010;88(4):e137-8
136. von Buelow M, Pape S, Hoerauf H. Systemic bevacizumab treatment of a juxtapapillary retinal haemangioma. Acta Ophthalmol Scand 2007;85(1):114-116
137. Ziemssen F, Voelker M, Inhoffen W, et al. Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy. Eye (Lond) 2007;21(8):1125-1126
138. Mennel S, Meyer CH, Callizo J. Combined intravitreal anti-vascular endothelial growth factor (Avastin) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma. Acta Ophthalmol 2010;88(5):610-613
139. Fong AH, Li KK, Wong D. Intravitreal ranibizumab, photodynamic therapy, and vitreous surgery for the treatment of juxtapapillary retinal capillary hemangioma. Graefes Arch Clin Exp Ophthalmol 2011;249(4):625-627
140. Singh AD, Turell ME, Topham AK. Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology 2011;118(9):1881-1885
141. Damato BE. Treatment selection for uveal melanoma. Dev Ophthalmol 2012;49:16-26
142. Damato B, Eleuteri A, Taktak AF, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res 2011;30(5):285-295
143. Sery TW, Shields JA, Augsburger JJ, et al. Photodynamic therapy of human ocular cancer. Ophthalmic Surg 1987;18:413-418
144. Kim RY, Hu LK, Foster BS, et al. Photodynamic therapy of pigmented choroidal melanomas of greater than 3-mm thickness. Ophthalmology 1996;103:2029-2036
145. Young LH, Howard MA, Hu LK, et al. Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Arch Ophthalmol 1996;114:186-192
146. Barbazetto IA, Lee TC, Rollins IS, et al. Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol 2003;135:898-899
147. Favilla I, Favilla ML, Gosbell AD, et al. Photodynamic therapy: A 5-year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture. Melanoma Res 1995;5(5):355-364
148. Lewis RA, Tse DT, Phelps CD, Weingeist TA. Neovascular glaucoma after photoradiation therapy for uveal melanoma. Arch Ophthalmol 1984;102(6):839-842
149. Wachtlin J, Bechrakis NE, Foerster MH. Photodynamic therapy with verteporfin for uveal melanoma. Ophthalmologe 2005;102(3):241-246
150. Sharma KV, Bowers N, Davids LM. Photodynamic therapy-induced killing is enhanced in depigmented metastatic melanoma cells. Cell Biol Int 2011;35(9):939-944
151. Campbell WG, Pejnovic TM. Tretament of amelanotic choroidal melanoma with photodynamic therapy. Retina 2011;E-Pub.
152. Garcia-Arumi J, Amselem L, Gunduz K, et al. Photodynamic therapy for symptomatic subretinal fluid related to choroidal nevus. Retina 2012;32(5):936-941
153. Blom DJ, Schuitmaker HJ, de Waard-Siebinga I, et al. Decreased expression of HLA class I on ocular melanoma cells following in vitro photodynamic therapy. Cancer Lett 1997;112(2):239-243
154. Pryds A, Larsen M. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy. Acta Ophthalmol 2011; E-Pub
155. Maruko I, Iida T, Sugano Y, et al. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010;117(9):1792-1799
156. Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996;16:203-213
157. Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol 2008;86:126-145
158. Bandello F, Virgili G, Lanzetta P, et al. ICG angiography and retinal pigment epithelial decompensation (CRSC and epitheliopathy). J Fr Ophtalmol 2001;24:448-451
159. Yannuzzi LA. Central serous chorioretinopathy: A personal perspective. Am J Ophthalmol 2010;149(3):361-363
160. Inoue R, Sawa M, Tsujikawa M, Gomi F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol 2010;149(3):441-6.e1-2
161. Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol 2008;86(2):126-145
162. Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: An update on pathogenesis and treatment. Eye (Lond) 2010;24(12):1743-1756
163. Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol 2011;22(3):166-173
164. Moon JW, Yu HG, Kim TW, et al. Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2009;247:1315-1323
165. Ober MD, Yannuzzi LA, Do DV, et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 2005;112:2088-2094
166. Tarantola RM, Law JC, Recchia FM, et al. Photodynamic therapy as treatment of chronic idiopathic central serous chorioretinopathy. Lasers Surg Med 2008;40:671-675
167. Ozmert E, Batioglu F. Fundus autofluorescence before and after photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmologica 2009;223:263-268
168. Lee PY, Kim KS, Lee WK. Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol 2009;53(1):52-56
169. Lai TY, Chan WM, Li H, et al. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: A short term pilot study. Br J Ophthalmol 2006;90(7):869-874
170. Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: One-year results of a prospective study. Retina 2008;28(1):85-93
171. Chan WM, Lai TY, Lai RY, et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: One-year results of a randomized controlled trial. Ophthalmology 2008;115(10):1756-1765
172. Zhao MW, Zhou P, Xiao HX, et al. Photodynamic therapy for acute central serous chorioretinopathy: The safe effective lowest dose of verteporfin. Retina 2009;29(8):1155-1161
173. Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: A nonrandomized clinical trial. Am J Ophthalmol 2010;149(2):307-315
174. Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 2011;152(5):784-792
175. Reibaldi M, Boscia F, Avitabile T, et al. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 2011;151(6):953-960
176. Senturk F, Karacorlu M, Ozdemir H, et al. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 2011;151(2):303-309
177. Kim SW, Oh J, Oh IK, Huh K. Retinal pigment epithelial tear after half fluence PDT for serous pigment epithelial detachment in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2009;40(3):300-303
178. Chan CK, Abraham P, Meyer CH, et al. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina 2010;30(2):203-211
179. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006;47(1):371-376
180. Sandell JL, Zhu TC. A review of in-vivo optical properties of human tissues and its impact on PDT. J Biophotonics 2011;4(11-12):773-787
181. Framme C, Flucke B, Birngruber R. Comparison of reduced and standard light application in photodynamic therapy of the eye in two rabbit models. Graefes Arch Clin Exp Ophthalmol 2006;244(7):773-781
182. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002;240(9):748-757
183. Henderson BW, Busch TM, Snyder JW. Fluence rate as a modulator of PDT mechanisms. Lasers Surg Med 2006;38(5):489-493
184. Busch TM, Wang HW, Wileyto EP, et al. Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate. Radiat Res 2010;174(3):331-340
185. Naghavi N, Miranbaygi MH, Sazgarnia A. Simulation of fractionated and continuous irradiation in photodynamic therapy: Study the differences between photobleaching and singlet oxygen dose deposition. Australas Phys Eng Sci Med 2011;34(2):203-211
186. Middelburg TA, Van Zaane F, De Bruijn HS, et al. Fractionated illumination at low fluence rate photodynamic therapy in mice. Photochem Photobiol 2010;86(5):1140-1146
187. Wang KK, Mitra S, Foster TH. A comprehensive mathematical model of microscopic dose deposition in photodynamic therapy. Med Phys 2007;34(1):282-293
188. Wang KK, Finlay JC, Busch TM, et al. Explicit dosimetry for photodynamic therapy: Macroscopic singlet oxygen modeling. J Biophotonics 2010;3(5-6):304-318
189. Jarvi MT, Patterson MS, Wilson BC. Insights into photodynamic therapy dosimetry: Simultaneous singlet oxygen luminescence and photosensitizer photobleaching measurements. Biophys J 2012;102(3):661-671
190. Aquaron R, Forzano O, Murati JL, et al. Simple, reliable and fast spectrofluorometric method for determination of plasma verteporfin (Visudyne) levels during photodynamic therapy for choroidal neovascularization. Cell Mol Biol (Noisy-le-grand) 2002;48(8):925-930
191. Samkoe KS, Clancy AA, Karotki A, et al. Complete blood vessel occlusion in the chick chorioallantoic membrane using two-photon excitation photodynamic therapy: Implications for treatment of wet age-related macular degeneration. J Biomed Opt 2007;12(3):034025
192. Mayo GL, Melendez RF, Kumar N, et al. Antibody-targeted photodynamic therapy. Am J Ophthalmol 2003;136(6):1151-1152
193. Lu F, Hu Z, Sinard J, et al. Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2009;50(8):3890-3896
194. Schmitt F, Juillerat-Jeanneret L. Drug Targeting Strategies for Photodynamic Therapy. Anticancer Agents Med Chem 2012;12(5):500-525
195. Mozaffarieh M, Schotzau A, Josifova T, Flammer J. The effect of ranibizumab versus photodynamic therapy on DNA damage in patients with exudative macular degeneration. Mol Vis 2009;15:1194-1199
196. Firczuk M, Nowis D, Gołab J. PDT-induced inflammatory and host responses. Photochem Photobiol Sci 2011;10(5):653-663
197. Rodrigues M, Meira D, Batista S, Carrilho MM. Accidental pregnancy exposure to verteporfin: Obstetrical and neonatal outcomes: A case report. Aust N Z J Obstet Gynaecol 2009;49(2):236-237
198. Jalil A, Mercieca K, Chaudhry NL, et al. Choroidal nonperfusion with significant subretinal exudation after PDT of predominantly classic CNV: An OCT and FFA study. Eur J Ophthalmol 2009;19:490-493
199. Schmidt-Erfurth U, Kiss C, Sacu S. The role of choroidal hypoperfusion associated with photodynamic therapy in neovascular age-related macular degeneration and the consequences for combination strategies. Prog Retin Eye Res 2009;28(2):145-154
200. Moon JW, Kim YJ, Khwarg SI, et al. Chorioretinal ischemia and angiogenic milieu following photodynamic therapy. Curr Eye Res 2010;35(4):314-321
201. Tsuchihashi T, Mori K, Peyman G, et al. Photodynamic effects on retinal oxygen saturation, blood flow, and electrophysiological function in patients with neovascular age-related macular degeneration. Retina 2009;29(10):1450-1456
202. Vinh Moreau-Gaudry V, Geiser M, Romanet JP, et al. Effects of photodynamic therapy on subfoveal blood flow in neovascular age-related macular degeneration patients. Eye (Lond) 2010;24(4):706-712
203. Turkuoglu P, Ozturkmen C, Ilhan N, et al. Retinal nitric oxide and malonyldialdehyde levels following photodynamic therapy. Indian J Ophthalmol 2011;59(1):5-8
204. Fujita K, Yuzawa M, Mori R. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: Short-term results. Retina 2011;31(4):772-778